PF Patients That Can Benefit From Esbriet

Esbriet (pirfenidone) is an anti-inflammatory and anti-fibrotic drug which has been found to be effective in slowing down the rate of fibrosis in the lung tissue of patients with pulmonary fibrosis (PF). But which PF patients would benefit most from the drug?

Esbriet may prevent acute flares in IPF patients after lung cancer surgery.

This video from MD Magazine TV identifies the types of patients that are ideal for the use of esbriet. Dr. Benjamin Kramer from Genentech discusses some of the criteria a patient must meet to be considered for esbriet. He shares that patients must be aware of the side effects of esbriet and how they’ll be managed, along with the fact that esbriet will not cure their pulmonary fibrosis but merely slow down the progression of the disease.

Find out more about the progression of pulmonary fibrosis. 

Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

2 comments

  1. mary young says:

    Wendy I just wanted to clarify that esbriet is not for pulmonary fibrosis patients it’s for idiopathic pulmonary fibrosis patients. There are thousands upon thousands of us with pulmonary fibrosis that are not idiopathic and we die everyday. Our lifespan is anywhere from 2 to 10 years. There are hundreds of clinical trials for ipf patients but there are none for us. Sorry but I just felt like I had to clarify this. There are too many of us that don’t see any hope in the future.

    • Jennifer Cannestra says:

      you are correct Mary, however, I believe there are expanded access trials for both FDA approved medications (Nintedanib and Pirfenidone), someone who has PF (and not IPF) may be eligible to participate in one of these trials – check: Clinicaltrials.gov then either drug to check for expanded access drug trials and centers where these are being held. Best wishes.

Leave a Comment

Your email address will not be published. Required fields are marked *